Why Today Is the Best Time to Buy Cortexyme Inc. [CRTX] Stock at $39.64

Cortexyme Inc. [CRTX] shares are up more than 50.45% this year and recently decreased -0.21% or -$8.31 to settle at $39.64. Analysts expect CRTX to grow earnings at a 18.30% annual rate over the next 5 years. CRTX has a short ratio of 16.90. This implies that the market is currently less bearish on the outlook for CRTX.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '22.
Small-cap Uranium stocks are booming in 2022! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here. .


On 4, December 2020, Cortexyme’s Phase 2/3 GAIN Trial of Atuzaginstat (COR388) in Patients with Alzheimer’s Disease Successfully Advances Past Interim Analysis. According to news published on Yahoo Finance, — GAIN Trial passes futility analysis and will continue to 1-year endpoint following the independent Data Monitoring Committee recommendation; topline results expected on time in December 2021 –.

Analyst Birdseye View:

The most recent analyst activity for Cortexyme Inc. [NASDAQ:CRTX] stock was on June 02, 2020, when it was Initiated with a Buy rating from Jefferies, which also raised its 12-month price target on the stock to $59. Before that, on June 24, 2020, H.C. Wainwright Recapitulated a Buy rating and elevated its amount target to $76. On June 03, 2019, JMP Securities Initiated a Mkt outperform rating and boosted its price target on this stock to $53. On June 03, 2019, Credit Suisse Initiated an Underperform rating and increased its price target to $14. On June 03, 2019, Canaccord Genuity Initiated a Buy rating and increased its price target to $42. On June 03, 2019, BofA/Merrill Initiated a Neutral rating and boosted its amount on this stock to $28.

In the past 52 weeks of trading, this stock has oscillated between a low of $27.88 and a peak of $73.84. Right now, according to Wall Street analyst the average 12-month amount target is $80.43. At the most recent market close, shares of Cortexyme Inc. [NASDAQ:CRTX] were valued at $39.64. According to the average price forecast, investors can expect a potential return of -7.24%.


Readers are usually of view to make a close observation to the indicators that support and make resistance before moving to any particular stock. As of now, the company’s stock is sitting at 45.86 points at 1st support level, the second support level is making up to 43.77. But as of 1st resistance point, this stock is sitting at 49.69 and at 51.43 for 2nd resistance point.

Cortexyme Inc. [CRTX] reported its earnings at -$0.73 per share in the fiscal quarter closing of 9/29/2020. The Analysts for Wall Street were expecting to report its earnings at -$0.62/share signifying the difference of -0.11 and -17.70% surprise value. Comparing the previous quarter ending of 6/29/2020, the stated earnings were -$0.6 calling estimates for -$0.62/share with the difference of 0.02 depicting the surprise of 3.20%.

Important Ratio’s To Watch

Meanwhile, turning our focus to liquidity, the Current Ratio for Cortexyme Inc. [NASDAQ:CRTX] is 8.70. Likewise, the Quick ratio is also the same, showing Cash ratio at 11.23. Now if looking for a valuation of this stock’s amount to book ratio is 13.06.

Insider Stories

The most recent insider trade was by EPIQ Capital Group, LLC, IA/Managing Member of 10% Owne, and it was the purchase of 2440.0 shares on Jun 12. EPIQ Capital Group, LLC, the IA/Managing Member of 10% Owne, completed a purchase of 6600.0 shares on Jun 11. On Jun 04, Lamond David, Director, completed a purchase of 49125.0 shares.